Guidant's $135 Mil. InControl Buy Adds Late-Stage Atrial Fibrillation Device
This article was originally published in The Gray Sheet
Guidant's $135 mil. InControl buy adds the Metrix atrial fibrillation technology to the firm's cardiac rhythm management unit, providing a complement to Guidant's market leading line of ventricular arrhythmia products and a platform for future growth in the $4 bil. worldwide cardiac rhythm management market.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.